Trial record 1 of 1 for:    NCT01351896
Previous Study | Return to List | Next Study

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This study is currently recruiting participants.
Verified January 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01351896
First received: May 10, 2011
Last updated: April 7, 2014
Last verified: January 2014

May 10, 2011
April 7, 2014
September 2011
December 2015   (final data collection date for primary outcome measure)
Proportion of patients who achieve an antibody response [ Time Frame: Up to 1 month ] [ Designated as safety issue: No ]
Defined as achieving at least a four-fold increase in post-vaccination serotype-specific IgG titers or serotype-specific immunoglobulin G concentrations of >= 0.35 ug/mL for 6 of 7 serotypes measured by a standard enzyme linked immunosorbent assay.
Proportion of patients who achieve an antibody response [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01351896 on ClinicalTrials.gov Archive Site
  • CR rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    95% confidence intervals will be estimated.
  • Time to first treatment [ Time Frame: From study entry to first therapy for progressive CLL, assessed up to 2 years ] [ Designated as safety issue: No ]
    Summarized and explored between treatment arms using Kaplan-Meier methods.
  • Overall survival [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    Summarized and explored between treatment arms using Kaplan-Meier methods.
  • Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Incidence of adverse events according to NCI CTCAE version 4 [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    Summarized by and across treatment arms, along with the type, severity, and perceived attribution to study.
  • CR rate following 2 years of lenalidomide [ Designated as safety issue: No ]
  • TFT and overall survival [ Designated as safety issue: No ]
  • Progression-free survival at 2 years [ Designated as safety issue: No ]
  • Adverse events according to NCI CTCAE v. 4 [ Designated as safety issue: Yes ]
  • Correlation of pharmacodynamic and pharmacokinetic markers with immunologic and disease response [ Designated as safety issue: No ]
  • Incidence of infection and invasive pneumococcal infections following treatment with the PCV13 vaccine [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features

This randomized phase II trial studies how well giving lenalidomide together with vaccine therapy works in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells.

PRIMARY OBJECTIVES:

I. To determine the proportion of early-stage, high-risk chronic lymphocytic leukemia (CLL) patients achieving a response (>= 4-fold increase from baseline and/or antibody concentrations >= 0.35 ug/mL in 6 of 7 type-specific anti-pneumococcal antibody levels) after 2 doses of pneumococcal 13-valent conjugated vaccine (Prevnar 13, PCV13 [pneumococcal polyvalent vaccine]) administered concurrently versus sequentially with low-dose lenalidomide.

SECONDARY OBJECTIVES:

I. To determine the complete response (CR) rate after 2 years of lenalidomide therapy.

II. To determine the time to first treatment (TFT), defined as the time from diagnosis to first non-lenalidomide therapy for progressive CLL as described by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria.

III. To determine the incidence of infection and invasive pneumococcal infections following treatment with the PCV13 vaccine and either concurrent or sequential lenalidomide.

IV. To determine the frequency of humoral and cellular immune response to CLL tumor antigens following treatment with the PCV13 vaccine and either concurrent or sequential lenalidomide.

V. To determine the safety and toxicity associated with long-term lenalidomide exposure.

VI. To perform correlative pharmacodynamic and pharmacokinetic studies and correlate these with vaccine/tumor immunologic and disease response.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (concurrent PCV13): Patients receive low-dose lenalidomide orally (PO) once daily on days 1-28. Treatment repeats every 28 days for at least 24 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 13-valent protein-conjugated pneumococcal vaccine (PCV13) intramuscularly (IM) on days 78 and 134 (courses 3 and 5).

ARM II (sequential PCV13): Patients receive PCV13 IM on days 1 and 78 (courses 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 106 (course 4).

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months thereafter.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • B-cell Chronic Lymphocytic Leukemia
  • Bacterial Infection
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • Noncontiguous Stage II Small Lymphocytic Lymphoma
  • Stage 0 Chronic Lymphocytic Leukemia
  • Stage I Chronic Lymphocytic Leukemia
  • Stage I Small Lymphocytic Lymphoma
  • Stage II Chronic Lymphocytic Leukemia
  • Biological: pneumococcal polyvalent vaccine
    Given IM (concurrently or sequentially)
    Other Names:
    • Pneumovax 23
    • Pnu-Imune 23
  • Drug: lenalidomide
    Given PO
    Other Names:
    • CC-5013
    • IMiD-1
    • Revlimid
  • Other: pharmacological study
    Correlative studies
    Other Name: pharmacological studies
  • Other: laboratory biomarker analysis
    Correlative studies
  • Experimental: Arm I (Concurrent PCV13 and lenalidomide)
    Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 courses in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on days 78 and 134 (courses 3 and 5).
    Interventions:
    • Biological: pneumococcal polyvalent vaccine
    • Drug: lenalidomide
    • Other: pharmacological study
    • Other: laboratory biomarker analysis
  • Experimental: Arm II (Sequential PCV13 and lenalidomide)
    Patients receive PCV13 IM on days 1 and 78 (courses 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 106 (course 4).
    Interventions:
    • Biological: pneumococcal polyvalent vaccine
    • Drug: lenalidomide
    • Other: pharmacological study
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
48
Not Provided
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have histologically identified chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as defined by the World Health Organization (WHO) classification of hematopoietic neoplasms
  • CLL/SLL cells must demonstrate one or more of the following high-risk genomic features:

    • Deletion (Del) (17p13.1) as detected by fluorescence in-situ hybridization (FISH) in > 20% of cells
    • Del(11q22.3) as detected by FISH in > 20% of cells
    • Complex karyotype (>= 3 cytogenetic abnormalities on stimulated karyotype)
    • Unmutated immunoglobulin variable heavy chain (IgVH) (>= 98% sequence homology compared with germline sequence)
  • Patients cannot meet any of the following consensus criteria for initiating treatment:

    • Progressive splenomegaly and/or lymphadenopathy identified by physical examination or radiographic studies
    • Progressive lymphocytosis with total white blood cell (WBC) >= 300,000/uL
    • Anemia (< 11 g/dL) or thrombocytopenia (< 100,000/uL) due to bone marrow involvement
    • Presence of unintentional weight loss > 10% over the preceding 6 months
    • National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or 3 fatigue
    • Fevers > 100.5 degrees or night sweats for > 2 weeks without evidence of infection
    • Progressive lymphocytosis with an increase of > 50% over a 2 month period or an anticipated doubling time of < 6 months
  • No prior therapy for CLL/SLL, including chemotherapy, radiotherapy, and/or immunotherapy will be allowed
  • Age >= 18 years and < 80 years (or with justification if older than 80 years)
  • Estimated life expectancy of greater than 24 months
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Total bilirubin =< 1.5 times upper limit of normal (ULN) (unless secondary to Gilbert disease)
  • Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate-pyruvate transaminase [SGPT]) =< 2.5 times ULN
  • Creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal according to the Cockcroft-Gault formula
  • Absolute neutrophil count (ANC) >= 1,500/uL
  • Platelet count >= 100,000/uL
  • Able to swallow capsules without difficulty and no history of malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide; further, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure

Exclusion Criteria:

  • Patients who have had any treatment for their CLL/SLL, including but not limited to chemotherapy, radiotherapy, or immunotherapy, prior to entering the study
  • No corticosteroid use will be permitted within two weeks prior to study, except for maintenance therapy for a non-malignant disease; maintenance therapy dose may not exceed 20 mg/day prednisone or equivalent
  • Patients who meet consensus criteria for the treatment of CLL/SLL
  • Patients may not be receiving any other investigational agents
  • Patients with a recent history (within 6 months of study entry) of deep vein thrombosis (DVT)/pulmonary embolism (PE) are not eligible; patients with a distant history (greater than 6 months before study entry) of venous thromboembolic disease are eligible, but should receive prophylactic aspirin or low molecular weight heparin
  • History of allergic reactions attributable to compounds of similar chemical or biologic composition to thalidomide, lenalidomide or any component of PCV7 or PCV13, including the diphtheria toxoid
  • Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject is considered by his or her physician to have a 2 year survival expectation
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible if they otherwise meet required hematologic parameters and are not receiving an antiviral agent with known or potential interaction with lenalidomide; because the primary aim of this study is to measure the immune response to pneumococcal vaccination, only patients with cluster of differentiation (CD)4 cell counts >= 200 and viral load < 50 will be eligible
  • Patients who have been treated for autoimmune hemolytic anemia or autoimmune thrombocytopenia within the last 6 months or are direct antiglobulin test/Coombs test or indirect antiglobulin test positive at the time of screening
  • Patients who have developed erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs in the past are excluded
  • Because of the potential for H2-blockers to modulate antibody response to pneumococcal vaccine, patients must discontinue treatment with H2-blockers (cimetidine, ranitidine, etc.) prior to beginning protocol therapy
Both
18 Years to 79 Years
No
Not Provided
United States
 
NCT01351896
NCI-2011-02584, NCI-2011-02584, 2011C0005, OSU-10156, CDR0000698438, OSU 10156, 8834, N01CM62207, P30CA016058, N01CM00070
Yes
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Jeffrey Jones Ohio State University
National Cancer Institute (NCI)
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP